Table 2.
Pathways for the “biosynthesis of cell constituents”
| Signaling pathways | HPG (d3) | PYS (d3) | PYS (d7) |
|---|---|---|---|
| Diphthamide biosynthesis | DPH6 | ||
| Dermatan, chondroitin or heparan sulfate biosynthesis | CHST1 | XYLT2, CSGALNACT2, HS3ST1, DSEL | CHST1 |
| S-adenosyl-L-methionine or cysteine biosynthesis III (mammalian) | MAT2A | MAT2A, EHMT1, NSUN4 | |
| Leukotriene biosynthesis | MGST3 | MGST3 | |
| Chondroitin or dermatan biosynthesis | CSGALNACT2 | ||
| Glycoaminoglycan-protein linkage region biosynthesis | XYLT2 | ||
| Inositol pyrophosphate biosynthesis | IPMK, IP6K2 | ||
| D-myo-inositol (1,3,4, 5)-trisphosphate or 1D-myo-inositol hexakisphosphate biosynthesis II | IPMK, ITPKB, PLCZ1 | ||
| D-myo-inositol (1,3,4, 5, 6)-tetrakisphosphate or 3-phosphoinositide biosynthesis | IPMK, PPP1R16B, DUSP1, PPP1R8, DUSP10, PPTC7, DUSP12, FGFR1, RNGTT, PTPRF | ||
| Citrulline biosynthesis | GLS, ARG2 | ||
| Lipoate biosynthesis and incorporation II | LIPT1 | ||
| Spermine or spermidine biosynthesis | AMD1 | ||
| Uridine-5′-phosphate biosynthesis or pyrimidine ribonucleotides de novo biosynthesis | UMPS, BLM | ||
| Fatty acid biosynthesis initiation II | OXSM | ||
| Serine, glycine or dTMP de novo biosynthesis | SHMT1 | ||
| Aspartate biosynthesis | GOT1 | ||
| CMP-N-acetylneuraminate biosynthesis I (eukaryotes) | GNE | ||
| Ceramide biosynthesis | KDSR | ||
| CDP-diacylglycerol biosynthesis 1, phosphatidylglycerol biosynthesis II (Non-plastidic) or triacylglycerol biosynthesis | TAMM41, AGPAT5 | ||
| Phosphatidylethanolamine biosynthesis II | ETNK1 | ||
| Dolichyl-diphosphooligosaccharide biosynthesis | ALG13 | ||
| Estrogen biosynthesis | CYP1A1, HSD17B2 | ||
| Stearate biosynthesis I (Animals) | ZADH2 |
Three separate RNA samples were included in each group (n = 3). The upregulated transcripts were highlighted in bold. Others were downregulated